Moleculin Biotec Stock Price, News & Analysis

Moleculin Biotech has received approval for its Phase 1/2 clinical trial of Annamycin combined with Cytarabine for treating acute myeloid leukemia (AML) in Poland. This follows promising preclinical data showing a 68% increase in overall survival (OS) with the combination treatment compared to Annamycin alone, and a 241% increase compared to Cytarabine alone. The trial is expected to start this quarter, with plans to expand to other European countries. Annamycin has demonstrated no cardiotoxicity and aims to overcome multidrug resistance seen in current treatments.

Moleculin Biotech, Inc. (Nasdaq: MBRX) has appointed Dr. Wolfram C. M. Dempke as its EU Chief Medical Officer to lead upcoming clinical trials in Europe. Dr. Dempke brings over 30 years of experience in oncology and hematology, having contributed to significant drug developments in various companies. He will oversee the Company's initiatives targeting highly resistant tumors. Moleculin's lead program, Annamycin, aims to address acute myeloid leukemia and soft tissue sarcoma with minimal cardiotoxicity. The Company continues to advance its clinical pipeline, focusing on unmet oncological needs.

Moleculin Biotech (Nasdaq: MBRX) announced the FDA's clearance of its Investigational New Drug (IND) application for WP1066, aimed at treating recurrent malignant glioma. The company plans to conduct a Phase 1 trial to assess the safety and efficacy of this treatment in adult patients. WP1066 has shown significant anti-tumor activity in preclinical studies and is currently being evaluated in pediatric brain tumor trials at Emory University, where preliminary results have demonstrated clinical improvement in a treated subject.

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced a corporate rebranding and the launch of a new website, aiming to align its branding with its vision to combat resistant cancers and viruses. The company emphasizes its commitment to overcoming medical challenges through innovative treatments, particularly highlighting Annamycin, a next-generation anthracycline that shows promise in treating relapsed acute myeloid leukemia and soft tissue sarcoma lung metastases without cardiotoxicity. The refreshed branding and website reflect Moleculin's dedication to advancing its clinical programs and development pipeline.

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced robust preclinical data for Annamycin in models of metastatic colorectal cancer. The findings indicate significant antitumor activity, showing a 272% extension of survival in lung metastasis models and complete elimination of tumors in liver metastasis models. Annamycin's efficacy positions it favorably for clinical studies, with ongoing development for acute myeloid leukemia and soft tissue sarcoma. The drug has Fast Track Status and Orphan Drug Designation from the FDA, reinforcing its potential in treating aggressive cancers.

Moleculin Biotech (Nasdaq: MBRX) reported positive preliminary safety and efficacy results from its Phase 1 AML study, leading to plans for a Phase 1/2 trial of Annamycin in combination with Cytarabine. Annamycin demonstrated no cardiotoxicity in trials for Acute Myeloid Leukemia and Soft Tissue Sarcoma. The FDA cleared the IND application for WP1122's use in GBM, with Phase 1a trials for COVID-19 also pending. Financial results show a 2021 R&D expense of $14.4 million, with a net loss of $15.9 million, but sufficient cash reserves to fund operations until 2024.

Moleculin Biotech, Inc. (Nasdaq: MBRX) will participate in the 2022 Virtual Growth Conference hosted by Maxim Group LLC and M-Vest from March 28-30, 2022. Walter Klemp, Chairman and CEO, will present during the event which will feature discussions from various sectors including biotech and healthcare. Attendees can view a video webcast of the presentation on-demand. Moleculin focuses on developing drug candidates for resistant tumors and viruses, with key programs like Annamycin for acute myeloid leukemia and WP1066 targeting brain tumors.

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that its Chairman and CEO, Walter Klemp, will present at the Oppenheimer 32^nd Annual Healthcare Conference on March 17, 2022, at 9:20 AM ET. The company focuses on developing drug candidates for resistant tumors and viruses, including its lead program, Annamycin, for treating acute myeloid leukemia and soft tissue sarcoma. The presentation will be available via a live webcast, and a replay will be archived for 90 days. Investors can expect virtual one-on-one meetings with management.